{"protocolSection":{"identificationModule":{"nctId":"NCT00616928","orgStudyIdInfo":{"id":"110464"},"organization":{"fullName":"GlaxoSmithKline","class":"INDUSTRY"},"briefTitle":"Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years","officialTitle":"A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccination Regimen in Adults Aged ≥18 Years"},"statusModule":{"statusVerifiedDate":"2016-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-01-23"},"primaryCompletionDateStruct":{"date":"2008-10-15","type":"ACTUAL"},"completionDateStruct":{"date":"2009-03-19","type":"ACTUAL"},"studyFirstSubmitDate":"2008-01-28","studyFirstSubmitQcDate":"2008-02-05","studyFirstPostDateStruct":{"date":"2008-02-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2013-12-19","resultsFirstSubmitQcDate":"2013-12-19","resultsFirstPostDateStruct":{"date":"2014-02-07","type":"ESTIMATED"},"dispFirstSubmitDate":"2009-05-20","dispFirstSubmitQcDate":"2009-08-13","dispFirstPostDateStruct":{"date":"2009-09-30","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-05-09","lastUpdatePostDateStruct":{"date":"2018-06-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GlaxoSmithKline","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The purpose of this Phase 3, observer-blind, placebo-controlled, multi-center study is to characterize the immunogenicity \\& safety of the investigation vaccination regimen of GSK 1557484A vaccine given to adults aged ≥18 years."},"conditionsModule":{"conditions":["Influenza"],"keywords":["vaccines","immunogenicity","human","safety","influenza"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":4561,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Influenza A (H5N1) 18-64Y Group","type":"EXPERIMENTAL","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.","interventionNames":["Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted"]},{"label":"Placebo 18-64Y Group","type":"PLACEBO_COMPARATOR","description":"Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.","interventionNames":["Biological: Placebo"]},{"label":"Influenza A (H5N1) >64Y Group","type":"EXPERIMENTAL","description":"Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.","interventionNames":["Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted"]},{"label":"Placebo >64Y Group","type":"PLACEBO_COMPARATOR","description":"Subjects aged \\> 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.","interventionNames":["Biological: Placebo"]},{"label":"Influenza A (H5N1) Group","type":"EXPERIMENTAL","description":"Pooled group of subjects aged \\>18 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.","interventionNames":["Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted"]},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR","description":"Pooled group of subjects aged \\>18 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.","interventionNames":["Biological: Placebo"]},{"label":"Influenza A (H5N1) 18-60Y Group","type":"EXPERIMENTAL","description":"Subjects aged 18-60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.","interventionNames":["Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted"]},{"label":"Placebo 18-60Y Group","type":"PLACEBO_COMPARATOR","description":"Subjects aged 18-60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.","interventionNames":["Biological: Placebo"]},{"label":"Influenza A (H5N1) >60Y Group","type":"EXPERIMENTAL","description":"Subjects aged \\>60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.","interventionNames":["Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted"]},{"label":"Placebo >60Y Group","type":"PLACEBO_COMPARATOR","description":"Subjects aged \\> 60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted","description":"Two intramuscular injections at Days 0 and 21.","armGroupLabels":["Influenza A (H5N1) 18-60Y Group","Influenza A (H5N1) 18-64Y Group","Influenza A (H5N1) >60Y Group","Influenza A (H5N1) >64Y Group","Influenza A (H5N1) Group"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Two intramuscular injections at Days 0 and 21.","armGroupLabels":["Placebo 18-60Y Group","Placebo 18-64Y Group","Placebo >60Y Group","Placebo >64Y Group","Placebo Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Seroconverted Subjects Against A/Indonesia/5/2005 (H5N1)","description":"A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) reciprocal HI titer \\< 1:10 and a post-vaccination (Day 42) reciprocal titer ≥ 1:40, or a pre-vaccination reciprocal HI titer ≥ 1:10 and at least a 4-fold increase in post-vaccination reciprocal titer against A/Indonesia/5/05 virus 21 days after the second dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.","timeFrame":"At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)"},{"measure":"Number of Seroprotected Subjects Against A/Indonesia/5/2005 (H5N1)","description":"A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.","timeFrame":"At Day 0 and Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)"},{"measure":"Number of Subjects With Any Solicited Local Symptoms.","description":"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.","timeFrame":"During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccine administration"},{"measure":"Number of Subjects With Any Solicited General Symptoms.","description":"Assessed solicited general symptoms were fatigue, headache, joint pain at other locations, muscle aches, shivering, sweating and temperature\\[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\\]. Any = occurrence of the symptom regardless of intensity grade.","timeFrame":"During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccine administration"},{"measure":"Number of Subjects With Any Unsolicited Adverse Events (AEs).","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.","timeFrame":"During a 21-day follow-up period for each vaccine administration, as well as overall (Day 0 through Day 84)"},{"measure":"Number of Subjects With Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","timeFrame":"From Day 0 through Day 182 and through Day 379."},{"measure":"Number of Subjects With Medically Attended Events (MAEs)","timeFrame":"From Day 0 through Day 182 and through Day 364."}],"secondaryOutcomes":[{"measure":"Number of Subjects With Serum Reciprocal HI Antibodies Against A/Indonesia/5/2005 Equal to or Above (≥) 1:10","timeFrame":"At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)"},{"measure":"Number of Subjects With A/Indonesia/5/05 Antibody Titers ≥ 1:10","timeFrame":"At Month 6 (Day 182) post Dose 1"},{"measure":"Number of Seroconverted Subjects Against A/Indonesia/5/2005 (H5N1)","description":"A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) reciprocal HI titer \\< 1:10 and a post-vaccination (Day 42) reciprocal titer ≥ 1:40, or a pre-vaccination reciprocal HI titer ≥ 1:10 and at least a 4-fold increase in post-vaccination reciprocal titer against A/Indonesia/5/05 virus 21 days after the second dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.","timeFrame":"At Month 6 (Day 182) after Dose 1"},{"measure":"Number of Seroprotected Subjects Against A/Indonesia/5/2005 (H5N1)","timeFrame":"At Month 6 (Day 182) after Dose 1"},{"measure":"Titers for Serum HI Antibodies Against A/Indonesia/5/05 (H5N1)","description":"Titers are presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was ≥ 1:10.","timeFrame":"At Month 6 (Day 182) after Dose 1"},{"measure":"Number of Subjects With a Vaccine Response to the Vaccine-homologous Virus and Drift Variant H5N1 Virus, as Assessed by Microneutralization Assays.","description":"Virus antibody response rates were defined as the number of subjects with antibody titers at Day 42 ≥ 4-fold the pre-vaccination antibody titers. The 2 strains assessed were Flu A/Indonesia/5/05 and Flu A/Vietnam/1194/04.","timeFrame":"At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)"},{"measure":"Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1) as Assessed by Microneutralization Assays","description":"Titers were expressed as Geometric Mean Titers (GMTs).","timeFrame":"At Day 0 and Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A male or female 18 years of age or greater at the time of the first vaccination.\n* Written informed consent obtained from the subject.\n* Among 18 to 49 year old subjects, good general health as established by medical history and clinical examination before entering into the study.\n* Among subjects \\> 49 years of age, stable health status within 1 month prior to enrollment.\n* Access to a consistent means of telephone contact.\n* Comprehension of the study requirements, ability to comprehend and comply with procedures for collection of short- and long-term safety data, expressed availability for the required study period, and ability and willingness to attend scheduled visits.\n\nExclusion Criteria:\n\n* Evidence of substance abuse or of neurological or psychiatric diagnoses which, even if clinically stable, are deemed by the investigator to render the potential subjectunable/unlikely to provide accurate safety reports.\n* Diagnosed with cancer, or treatment for cancer, within 3 years.\n* An oral temperature ≥37.8º C, or acute symptoms greater than \"mild\" severity on the scheduled date of first vaccination.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus infection.\n* Receipt of systemic glucocorticoids within 1 month of study enrollment, or any other cytotoxic or immunosuppressive drug within 6 months of study enrollment.\n* Any significant disorder of coagulation or treatment with Coumadin derivatives or heparin.\n* Administration of any vaccines within 30 days before study enrollment.\n* Previous administration of any H5N1 vaccine.\n* Use of any investigational or non-registered product or planned participation in another investigational study within 30 days prior to study enrollment, or during the 364 days following the first test article dose. Use of any investigational or non-registered product with immunosuppressive properties is exclusionary at any time during the trial.\n* Receipt of any immunoglobulins and/or any blood products within 3 months of study enrollment or planned administration of any of these products during the study period.\n* Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine.\n* Known pregnancy or a positive urine beta-human chorionic gonadotropin test result prior to either vaccination.\n* Lactating or nursing.\n* Women of child bearing potential who lack a history of reliable contraceptive practices. The provision of this history does NOT replace the requirement to perform, and obtain negative results in pregnancy urine tests prior to treatments.\n* Known use of an analgesic or antipyretic medication within 12 hours prior to first treatment.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"GSK Clinical Trials","affiliation":"GlaxoSmithKline","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"GSK Investigational Site","city":"Huntsville","state":"Alabama","zip":"35802","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"GSK Investigational Site","city":"Phoenix","state":"Arizona","zip":"85020","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"GSK Investigational Site","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"GSK Investigational Site","city":"Jacksonville","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"GSK Investigational Site","city":"Melbourne","state":"Florida","zip":"32935","country":"United States","geoPoint":{"lat":28.08363,"lon":-80.60811}},{"facility":"GSK Investigational Site","city":"Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"GSK Investigational Site","city":"Pembroke Pines","state":"Florida","zip":"33024","country":"United States","geoPoint":{"lat":26.00315,"lon":-80.22394}},{"facility":"GSK Investigational Site","city":"Stockbridge","state":"Georgia","zip":"30281","country":"United States","geoPoint":{"lat":33.54428,"lon":-84.23381}},{"facility":"GSK Investigational Site","city":"Chicago","state":"Illinois","zip":"60610","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"GSK Investigational Site","city":"Peoria","state":"Illinois","zip":"61602","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"GSK Investigational Site","city":"South Bend","state":"Indiana","zip":"46601","country":"United States","geoPoint":{"lat":41.68338,"lon":-86.25001}},{"facility":"GSK Investigational Site","city":"Lenexa","state":"Kansas","zip":"66219","country":"United States","geoPoint":{"lat":38.95362,"lon":-94.73357}},{"facility":"GSK Investigational Site","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"GSK Investigational Site","city":"Metairie","state":"Louisiana","zip":"70006","country":"United States","geoPoint":{"lat":29.98409,"lon":-90.15285}},{"facility":"GSK Investigational Site","city":"Rockville","state":"Maryland","zip":"20850","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"GSK Investigational Site","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"GSK Investigational Site","city":"Missoula","state":"Montana","zip":"59801","country":"United States","geoPoint":{"lat":46.87215,"lon":-113.994}},{"facility":"GSK Investigational Site","city":"Las Vegas","state":"Nevada","zip":"89104","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"GSK Investigational Site","city":"Edison","state":"New Jersey","zip":"08817","country":"United States","geoPoint":{"lat":40.51872,"lon":-74.4121}},{"facility":"GSK Investigational Site","city":"Poughkeepsie","state":"New York","zip":"12601","country":"United States","geoPoint":{"lat":41.70037,"lon":-73.92097}},{"facility":"GSK Investigational Site","city":"Rochester","state":"New York","zip":"14609","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"GSK Investigational Site","city":"Raleigh","state":"North Carolina","zip":"27612","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"facility":"GSK Investigational Site","city":"Cleveland","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"GSK Investigational Site","city":"Erie","state":"Pennsylvania","zip":"16506","country":"United States","geoPoint":{"lat":42.12922,"lon":-80.08506}},{"facility":"GSK Investigational Site","city":"Pittsburgh","state":"Pennsylvania","zip":"15236","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"GSK Investigational Site","city":"Spartanburg","state":"South Carolina","zip":"29303","country":"United States","geoPoint":{"lat":34.94957,"lon":-81.93205}},{"facility":"GSK Investigational Site","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"GSK Investigational Site","city":"Austin","state":"Texas","zip":"78705","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"GSK Investigational Site","city":"Fort Worth","state":"Texas","zip":"76135","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"GSK Investigational Site","city":"San Angelo","state":"Texas","zip":"76904","country":"United States","geoPoint":{"lat":31.46377,"lon":-100.43704}},{"facility":"GSK Investigational Site","city":"Halifax","state":"Nova Scotia","zip":"B3K 6R8","country":"Canada","geoPoint":{"lat":44.64269,"lon":-63.57688}},{"facility":"GSK Investigational Site","city":"Truro","state":"Nova Scotia","zip":"B2N 1L2","country":"Canada","geoPoint":{"lat":45.36685,"lon":-63.26538}},{"facility":"GSK Investigational Site","city":"Greater Sudbury","state":"Ontario","zip":"P3E 6C3","country":"Canada","geoPoint":{"lat":46.49,"lon":-80.99001}},{"facility":"GSK Investigational Site","city":"London","state":"Ontario","zip":"N5W 6A2","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"GSK Investigational Site","city":"Sarnia","state":"Ontario","zip":"N7T 4X3","country":"Canada","geoPoint":{"lat":42.97866,"lon":-82.40407}},{"facility":"GSK Investigational Site","city":"Woodstock","state":"Ontario","zip":"N4S 4G3","country":"Canada","geoPoint":{"lat":43.13339,"lon":-80.7497}},{"facility":"GSK Investigational Site","city":"Pointe-Claire","state":"Quebec","zip":"H9R 4S3","country":"Canada","geoPoint":{"lat":45.44868,"lon":-73.81669}},{"facility":"GSK Investigational Site","city":"Québec","state":"Quebec","zip":"G1E 7G9","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"GSK Investigational Site","city":"Saint Romuald","state":"Quebec","zip":"G6W 5M6","country":"Canada","geoPoint":{"lat":46.75818,"lon":-71.23921}},{"facility":"GSK Investigational Site","city":"Sherbrooke","state":"Quebec","zip":"J1H 4J6","country":"Canada","geoPoint":{"lat":45.40008,"lon":-71.89908}}]},"referencesModule":{"references":[{"pmid":"21606531","type":"DERIVED","citation":"Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, Poling T, Riff D, Baron M, Frenette L, Sheldon E, Collins H, Shepard M, Dionne M, Brune D, Ferguson L, Vaughn D, Li P, Fries L. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis. 2011 Jun 15;203(12):1729-38. doi: 10.1093/infdis/jir172."}],"seeAlsoLinks":[{"label":"Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.","url":"https://www.clinicalstudydatarequest.com"}],"availIpds":[{"id":"110464","type":"Statistical Analysis Plan","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"110464","type":"Clinical Study Report","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"110464","type":"Annotated Case Report Form","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"110464","type":"Individual Participant Data Set","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"110464","type":"Dataset Specification","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"110464","type":"Informed Consent Form","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"110464","type":"Study Protocol","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Influenza A (H5N1) 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"FG001","title":"Placebo 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"FG002","title":"Influenza A (H5N1) >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"FG003","title":"Placebo >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"2304"},{"groupId":"FG001","numSubjects":"768"},{"groupId":"FG002","numSubjects":"1118"},{"groupId":"FG003","numSubjects":"371"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2242"},{"groupId":"FG001","numSubjects":"750"},{"groupId":"FG002","numSubjects":"1101"},{"groupId":"FG003","numSubjects":"364"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"17"},{"groupId":"FG003","numSubjects":"7"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"51"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"15"},{"groupId":"FG003","numSubjects":"5"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Influenza A (H5N1) 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"BG001","title":"Placebo 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"BG002","title":"Influenza A (H5N1) >64Y Group","description":"Influenza A (H5N1) \\>64Y Group Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"BG003","title":"Placebo >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"2304"},{"groupId":"BG001","value":"768"},{"groupId":"BG002","value":"1118"},{"groupId":"BG003","value":"371"},{"groupId":"BG004","value":"4561"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"38.5","spread":"13.64"},{"groupId":"BG001","value":"38.7","spread":"13.58"},{"groupId":"BG002","value":"71.9","spread":"5.49"},{"groupId":"BG003","value":"72.1","spread":"5.41"},{"groupId":"BG004","value":"49.5","spread":"19.50"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"424"},{"groupId":"BG002","value":"621"},{"groupId":"BG003","value":"196"},{"groupId":"BG004","value":"2569"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"976"},{"groupId":"BG001","value":"344"},{"groupId":"BG002","value":"497"},{"groupId":"BG003","value":"175"},{"groupId":"BG004","value":"1992"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Seroconverted Subjects Against A/Indonesia/5/2005 (H5N1)","description":"A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) reciprocal HI titer \\< 1:10 and a post-vaccination (Day 42) reciprocal titer ≥ 1:40, or a pre-vaccination reciprocal HI titer ≥ 1:10 and at least a 4-fold increase in post-vaccination reciprocal titer against A/Indonesia/5/05 virus 21 days after the second dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.","populationDescription":"The analysis was based on the ATP cohort for analysis of immunogenicity, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)","groups":[{"id":"OG000","title":"Influenza A (H5N1) 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG001","title":"Placebo 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG002","title":"Influenza A (H5N1) >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG003","title":"Placebo >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1571"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"396"},{"groupId":"OG003","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1427"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"293"},{"groupId":"OG003","value":"1"}]}]}]},{"type":"PRIMARY","title":"Number of Seroprotected Subjects Against A/Indonesia/5/2005 (H5N1)","description":"A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.","populationDescription":"The analysis was based on the ATP cohort for analysis of immunogenicity, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"At Day 0 and Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)","groups":[{"id":"OG000","title":"Influenza A (H5N1) 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm"},{"id":"OG001","title":"Placebo 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG002","title":"Influenza A (H5N1) >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG003","title":"Placebo >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1571"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"396"},{"groupId":"OG003","value":"40"}]}],"classes":[{"title":"Day 0","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"0"}]}]},{"title":"Day 42","categories":[{"measurements":[{"groupId":"OG000","value":"1467"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"334"},{"groupId":"OG003","value":"1"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Any Solicited Local Symptoms.","description":"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.","populationDescription":"The analysis was based on the Total Vaccinated cohort, on subjects with symptom sheets completed.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccine administration","groups":[{"id":"OG000","title":"Influenza A (H5N1) 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm"},{"id":"OG001","title":"Placebo 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG002","title":"Influenza A (H5N1) >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG003","title":"Placebo >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG004","title":"Influenza A (H5N1) Group","description":"Pooled group of subjects aged \\>18 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG005","title":"Placebo Group","description":"Pooled group of subjects aged \\>18 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2267"},{"groupId":"OG001","value":"754"},{"groupId":"OG002","value":"1109"},{"groupId":"OG003","value":"368"},{"groupId":"OG004","value":"3376"},{"groupId":"OG005","value":"1122"}]}],"classes":[{"title":"Pain","categories":[{"measurements":[{"groupId":"OG000","value":"2024"},{"groupId":"OG001","value":"171"},{"groupId":"OG002","value":"784"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"2808"},{"groupId":"OG005","value":"224"}]}]},{"title":"Redness","categories":[{"measurements":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"106"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"287"},{"groupId":"OG005","value":"8"}]}]},{"title":"Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"110"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"351"},{"groupId":"OG005","value":"8"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Any Solicited General Symptoms.","description":"Assessed solicited general symptoms were fatigue, headache, joint pain at other locations, muscle aches, shivering, sweating and temperature\\[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\\]. Any = occurrence of the symptom regardless of intensity grade.","populationDescription":"The analysis was based on the Total Vaccinated cohort, on subjects with symptom sheets completed.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccine administration","groups":[{"id":"OG000","title":"Influenza A (H5N1) 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG001","title":"Placebo 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG002","title":"Influenza A (H5N1) >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG003","title":"Placebo >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG004","title":"Influenza A (H5N1) Group","description":"Pooled group of subjects aged \\>18 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG005","title":"Placebo Group","description":"Pooled group of subjects aged \\>18 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2266"},{"groupId":"OG001","value":"755"},{"groupId":"OG002","value":"1109"},{"groupId":"OG003","value":"368"},{"groupId":"OG004","value":"3375"},{"groupId":"OG005","value":"1123"}]}],"classes":[{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"890"},{"groupId":"OG001","value":"189"},{"groupId":"OG002","value":"258"},{"groupId":"OG003","value":"64"},{"groupId":"OG004","value":"1148"},{"groupId":"OG005","value":"253"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"932"},{"groupId":"OG001","value":"249"},{"groupId":"OG002","value":"247"},{"groupId":"OG003","value":"63"},{"groupId":"OG004","value":"1179"},{"groupId":"OG005","value":"312"}]}]},{"title":"Joint pain at other location","categories":[{"measurements":[{"groupId":"OG000","value":"645"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"208"},{"groupId":"OG003","value":"39"},{"groupId":"OG004","value":"853"},{"groupId":"OG005","value":"136"}]}]},{"title":"Muscle aches","categories":[{"measurements":[{"groupId":"OG000","value":"1188"},{"groupId":"OG001","value":"175"},{"groupId":"OG002","value":"338"},{"groupId":"OG003","value":"56"},{"groupId":"OG004","value":"1526"},{"groupId":"OG005","value":"231"}]}]},{"title":"Shivering","categories":[{"measurements":[{"groupId":"OG000","value":"456"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"107"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"563"},{"groupId":"OG005","value":"109"}]}]},{"title":"Sweating","categories":[{"measurements":[{"groupId":"OG000","value":"314"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"48"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"362"},{"groupId":"OG005","value":"109"}]}]},{"title":"Temperature","categories":[{"measurements":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"156"},{"groupId":"OG005","value":"109"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Any Unsolicited Adverse Events (AEs).","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"During a 21-day follow-up period for each vaccine administration, as well as overall (Day 0 through Day 84)","groups":[{"id":"OG000","title":"Influenza A (H5N1) 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG001","title":"Placebo 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG002","title":"Influenza A (H5N1) >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG003","title":"Placebo >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"768"},{"groupId":"OG002","value":"1118"},{"groupId":"OG003","value":"371"}]}],"classes":[{"title":"Unsolicited AEs Days 0-21","categories":[{"measurements":[{"groupId":"OG000","value":"914"},{"groupId":"OG001","value":"289"},{"groupId":"OG002","value":"399"},{"groupId":"OG003","value":"113"}]}]},{"title":"Unsolicited AEs Days 0-84","categories":[{"measurements":[{"groupId":"OG000","value":"1017"},{"groupId":"OG001","value":"321"},{"groupId":"OG002","value":"467"},{"groupId":"OG003","value":"130"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"From Day 0 through Day 182 and through Day 379.","groups":[{"id":"OG000","title":"Influenza A (H5N1) 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG001","title":"Placebo 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG002","title":"Influenza A (H5N1) >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG003","title":"Placebo >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"768"},{"groupId":"OG002","value":"1118"},{"groupId":"OG003","value":"371"}]}],"classes":[{"title":"Subjects with SAEs Days 0-182","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"43"},{"groupId":"OG003","value":"14"}]}]},{"title":"Subjects with SAEs Days 0-379","categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"65"},{"groupId":"OG003","value":"30"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Medically Attended Events (MAEs)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"From Day 0 through Day 182 and through Day 364.","groups":[{"id":"OG000","title":"Influenza A (H5N1) 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG001","title":"Placebo 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG002","title":"Influenza A (H5N1) >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG003","title":"Placebo >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"768"},{"groupId":"OG002","value":"1118"},{"groupId":"OG003","value":"371"}]}],"classes":[{"title":"Subjects with MAEs Days 0-182","categories":[{"measurements":[{"groupId":"OG000","value":"480"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"298"},{"groupId":"OG003","value":"92"}]}]},{"title":"Subjects with MAEs Days 0-379","categories":[{"measurements":[{"groupId":"OG000","value":"627"},{"groupId":"OG001","value":"212"},{"groupId":"OG002","value":"400"},{"groupId":"OG003","value":"134"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serum Reciprocal HI Antibodies Against A/Indonesia/5/2005 Equal to or Above (≥) 1:10","populationDescription":"The analysis was based on the ATP cohort for analysis of immunogenicity, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)","groups":[{"id":"OG000","title":"Influenza A (H5N1) 18-60Y Group","description":"Subjects aged 18-60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG001","title":"Placebo 18-60Y Group","description":"Subjects aged 18-60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG002","title":"Influenza A (H5N1) >60Y Group","description":"Subjects aged \\>60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG003","title":"Placebo >60Y Group","description":"Subjects aged \\> 60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1488"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"479"},{"groupId":"OG003","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1391"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"410"},{"groupId":"OG003","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With A/Indonesia/5/05 Antibody Titers ≥ 1:10","populationDescription":"The analysis was based on the ATP cohort for analysis of immunogenicity - Month 6, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available at Month 6","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"At Month 6 (Day 182) post Dose 1","groups":[{"id":"OG000","title":"Influenza A (H5N1) 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG001","title":"Placebo 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG002","title":"Influenza A (H5N1) >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG003","title":"Placebo ˃ 64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"366"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"91"},{"groupId":"OG003","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Seroconverted Subjects Against A/Indonesia/5/2005 (H5N1)","description":"A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) reciprocal HI titer \\< 1:10 and a post-vaccination (Day 42) reciprocal titer ≥ 1:40, or a pre-vaccination reciprocal HI titer ≥ 1:10 and at least a 4-fold increase in post-vaccination reciprocal titer against A/Indonesia/5/05 virus 21 days after the second dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.","populationDescription":"The analysis was based on the ATP cohort for analysis of immunogenicity - Month 6, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available at Month 6","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"At Month 6 (Day 182) after Dose 1","groups":[{"id":"OG000","title":"Influenza A (H5N1) 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG001","title":"Placebo 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG002","title":"Influenza A (H5N1) >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG003","title":"Placebo >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"366"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"91"},{"groupId":"OG003","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"59"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Seroprotected Subjects Against A/Indonesia/5/2005 (H5N1)","populationDescription":"The analysis was based on the ATP cohort for analysis of immunogenicity - Month 6, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available at Month 6","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"At Month 6 (Day 182) after Dose 1","groups":[{"id":"OG000","title":"Influenza A (H5N1) 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG001","title":"Placebo 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG002","title":"Influenza A (H5N1) >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG003","title":"Placebo >64Y Group","description":"Subjects aged \\>64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"366"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"91"},{"groupId":"OG003","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"SECONDARY","title":"Titers for Serum HI Antibodies Against A/Indonesia/5/05 (H5N1)","description":"Titers are presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was ≥ 1:10.","populationDescription":"The analysis was based on the ATP cohort for analysis of immunogenicity - Month 6, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables at Month 6.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"At Month 6 (Day 182) after Dose 1","groups":[{"id":"OG000","title":"Influenza A (H5N1) 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG001","title":"Placebo 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG002","title":"Influenza A (H5N1) >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG003","title":"Placebo ˃ 64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"366"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.2","lowerLimit":"31.0","upperLimit":"42.2"},{"groupId":"OG001","value":"5.5","lowerLimit":"4.8","upperLimit":"6.5"},{"groupId":"OG002","value":"44.8","lowerLimit":"33.3","upperLimit":"60.4"},{"groupId":"OG003","value":"5.4","lowerLimit":"4.6","upperLimit":"6.3"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With a Vaccine Response to the Vaccine-homologous Virus and Drift Variant H5N1 Virus, as Assessed by Microneutralization Assays.","description":"Virus antibody response rates were defined as the number of subjects with antibody titers at Day 42 ≥ 4-fold the pre-vaccination antibody titers. The 2 strains assessed were Flu A/Indonesia/5/05 and Flu A/Vietnam/1194/04.","populationDescription":"The analysis was based on the ATP cohort for analysis of immunogenicity, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)","groups":[{"id":"OG000","title":"Influenza A (H5N1) 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG001","title":"Influenza A (H5N1) >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"46"}]}],"classes":[{"title":"A/Indonesia/5/05","categories":[{"measurements":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"36"}]}]},{"title":"A/Vietnam/1194/04","categories":[{"measurements":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"12"}]}]}]},{"type":"SECONDARY","title":"Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1) as Assessed by Microneutralization Assays","description":"Titers were expressed as Geometric Mean Titers (GMTs).","populationDescription":"The analysis was based on the ATP cohort for analysis of immunogenicity, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"At Day 0 and Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)","groups":[{"id":"OG000","title":"Influenza A (H5N1) 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."},{"id":"OG001","title":"Influenza A (H5N1) >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"46"}]}],"classes":[{"title":"A/Indonesia/5/05, Day 0","categories":[{"measurements":[{"groupId":"OG000","value":"22.4","lowerLimit":"19.9","upperLimit":"25.3"},{"groupId":"OG001","value":"52.4","lowerLimit":"39.2","upperLimit":"69.8"}]}]},{"title":"A/Indonesia/5/05, Day 42","categories":[{"measurements":[{"groupId":"OG000","value":"1450.6","lowerLimit":"1266.9","upperLimit":"1660.9"},{"groupId":"OG001","value":"631.1","lowerLimit":"444.5","upperLimit":"896.1"}]}]},{"title":"A/Vietnam/1194/04, Day 0","categories":[{"measurements":[{"groupId":"OG000","value":"29.9","lowerLimit":"25.7","upperLimit":"34.9"},{"groupId":"OG001","value":"94.4","lowerLimit":"68.4","upperLimit":"130.3"}]}]},{"title":"A/Vietnam/1194/04, Day 42","categories":[{"measurements":[{"groupId":"OG000","value":"163.1","lowerLimit":"145.6","upperLimit":"182.8"},{"groupId":"OG001","value":"213.4","lowerLimit":"165.5","upperLimit":"275.1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"SAEs were collected up to Day 182 and up to study end at Day 379. Unsolicited AEs were collected up to Day 20 and up to Day 84. Systematically-assessed symptoms were collected up to Day 6 post vaccination.","eventGroups":[{"id":"EG000","title":"Influenza A (H5N1) 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.","seriousNumAffected":24,"seriousNumAtRisk":2304,"otherNumAffected":2087,"otherNumAtRisk":2304},{"id":"EG001","title":"Placebo 18-64Y Group","description":"Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.","seriousNumAffected":7,"seriousNumAtRisk":768,"otherNumAffected":405,"otherNumAtRisk":768},{"id":"EG002","title":"Influenza A (H5N1) >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.","seriousNumAffected":43,"seriousNumAtRisk":1118,"otherNumAffected":866,"otherNumAtRisk":1118},{"id":"EG003","title":"Placebo >64Y Group","description":"Subjects aged \\> 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.","seriousNumAffected":14,"seriousNumAtRisk":371,"otherNumAffected":141,"otherNumAtRisk":371}],"seriousEvents":[{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":4,"numAtRisk":1118},{"groupId":"EG003","numAffected":2,"numAtRisk":371}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":3,"numAtRisk":1118},{"groupId":"EG003","numAffected":2,"numAtRisk":371}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":2,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":3,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":2,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":3,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":2,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Thyroid cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":2,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Abdominal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":2,"numAtRisk":371}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":2,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":2,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Calculus bladder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Coronary artery stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":2,"numAtRisk":371}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":2,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Diastolic dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":2,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":2,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":2,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Affective disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Arthritis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Atrial septal defect","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Biliary dyskinesia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Biopsy liver normal","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Brain neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Breast cancer recurrent","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Bronchitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Caecitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Cardiac disorder","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Cardiomegaly","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Carotid artery dissection","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Carotid artery stenosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Cholangitis suppurative","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Cholecystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Colitis ischaemic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Coronary artery occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Diabetic complication","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Diarrhoea infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Enteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Fibula fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Forearm fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Gallbladder disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"HIV test positive","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Hamartoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Hepatitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Hiatus hernia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Hypersensitivity","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Hypertrophic cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Hypotension","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Ischaemic stroke","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Left atrial dilatation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Liver disorder","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Lymph node cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Lymphoma","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Major depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Mania","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Melaena","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Meniscus lesion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Mental disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Metastases to liver","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Mountain sickness acute","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Muscle strain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Nasal septum deviation","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Neonatal respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Ovarian cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Pancreatitis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Peripheral vascular disorder","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Pneumonia pneumococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Pyelonephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Radiculitis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Rectal cancer stage 0","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Renal cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Renal tubular acidosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Renal vessel disorder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Rotator cuff syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Seminoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Sick sinus syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Spinal column stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Spinal cord compression","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Spondylolisthesis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Syncope","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Synovial cyst","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Tibia fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Tongue carcinoma stage I","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Tongue neoplasm malignant stage unspecified","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Toxic nodular goitre","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Tracheobronchitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":1,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Transplant rejection","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Ulna fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Urinary retention postoperative","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]},{"term":"Urinary tract infection","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":0,"numAtRisk":1118},{"groupId":"EG003","numAffected":1,"numAtRisk":371}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2304},{"groupId":"EG001","numAffected":0,"numAtRisk":768},{"groupId":"EG002","numAffected":1,"numAtRisk":1118},{"groupId":"EG003","numAffected":0,"numAtRisk":371}]}],"otherEvents":[{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2024,"numAtRisk":2267},{"groupId":"EG001","numAffected":171,"numAtRisk":754},{"groupId":"EG002","numAffected":784,"numAtRisk":1109},{"groupId":"EG003","numAffected":53,"numAtRisk":368}]},{"term":"Redness","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":181,"numAtRisk":2267},{"groupId":"EG001","numAffected":7,"numAtRisk":754},{"groupId":"EG002","numAffected":106,"numAtRisk":1109},{"groupId":"EG003","numAffected":1,"numAtRisk":368}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":241,"numAtRisk":2267},{"groupId":"EG001","numAffected":7,"numAtRisk":754},{"groupId":"EG002","numAffected":110,"numAtRisk":1109},{"groupId":"EG003","numAffected":1,"numAtRisk":368}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":890,"numAtRisk":2266},{"groupId":"EG001","numAffected":189,"numAtRisk":755},{"groupId":"EG002","numAffected":258,"numAtRisk":1109},{"groupId":"EG003","numAffected":64,"numAtRisk":371}]},{"term":"Headache","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":932,"numAtRisk":2266},{"groupId":"EG001","numAffected":249,"numAtRisk":755},{"groupId":"EG002","numAffected":247,"numAtRisk":1109},{"groupId":"EG003","numAffected":63,"numAtRisk":371}]},{"term":"Joint pain at other location","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":645,"numAtRisk":2266},{"groupId":"EG001","numAffected":97,"numAtRisk":755},{"groupId":"EG002","numAffected":208,"numAtRisk":1109},{"groupId":"EG003","numAffected":39,"numAtRisk":371}]},{"term":"Muscle aches","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1188,"numAtRisk":2266},{"groupId":"EG001","numAffected":175,"numAtRisk":755},{"groupId":"EG002","numAffected":338,"numAtRisk":1109},{"groupId":"EG003","numAffected":56,"numAtRisk":371}]},{"term":"Shivering","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":456,"numAtRisk":2266},{"groupId":"EG001","numAffected":87,"numAtRisk":755},{"groupId":"EG002","numAffected":107,"numAtRisk":1109},{"groupId":"EG003","numAffected":22,"numAtRisk":371}]},{"term":"Sweating","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":314,"numAtRisk":2266},{"groupId":"EG001","numAffected":67,"numAtRisk":755},{"groupId":"EG002","numAffected":48,"numAtRisk":1109},{"groupId":"EG003","numAffected":15,"numAtRisk":371}]},{"term":"Temperature (Oral)","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":121,"numAtRisk":2266},{"groupId":"EG001","numAffected":32,"numAtRisk":755},{"groupId":"EG002","numAffected":35,"numAtRisk":1109},{"groupId":"EG003","numAffected":6,"numAtRisk":371}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":116,"numAtRisk":2304},{"groupId":"EG001","numAffected":29,"numAtRisk":768},{"groupId":"EG002","numAffected":40,"numAtRisk":1118},{"groupId":"EG003","numAffected":11,"numAtRisk":371}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":91,"numAtRisk":2304},{"groupId":"EG001","numAffected":39,"numAtRisk":768},{"groupId":"EG002","numAffected":34,"numAtRisk":1118},{"groupId":"EG003","numAffected":12,"numAtRisk":371}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"GSK Response Center","organization":"GlaxoSmithKline","phone":"866-435-7343"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}